

Name of the Issuer:		Suraksha Diagnostic Limited	Last updated on	15-Feb-25
1	<b>Type of Issue (IPO / FPO)</b> Source: Prospectus dated December 3, 2024	IPO		
2	<b>Issue Size (Rs. Million)</b> - Fresh Issue Size (Rs. Millions) - Offer for Sale Component (Rs. Millions) Source: Prospectus dated December 3, 2024	8,462.49 - 8,462.49		
3	<b>Grade of issue along with name of the rating agency</b> Name Grade Source: Prospectus dated December 3, 2024	Not Applicable Not Applicable		
4	<b>Subscription Level (Number of times)</b> Source: Minutes for basis of allotment dated December 3, 2024 <i>*The above figure is after technical rejections and excluding Anchor portion</i>	1.26*		
5	<b>QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges</b>			
	<b>Particulars</b>	<b>%</b>		
	(i) allotment in the issue <sup>(1)(2)</sup>	32.32%		
	(ii) at the end of 1st Quarter immediately after the listing (December 31, 2024)*	35.83%		
	(iii) at the end of 1st FY (March 31, 2025)*	Not Available		
	(iv) at the end of 2nd FY (March 31, 2026)*	Not Available		
	(v) at the end of 3rd FY (March 31, 2027)*	Not Available		
	<i>*QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.</i>			
	<i>(1) Source: Institutions (domestic + foreign) holding as disclosed in the stock exchange filing</i>			
	<i>(2) Includes the shareholding of Orbimed Asia II Mauritius Limited, who is a pre-existing shareholder of the Company</i>			

#### 6 Financials of the issuer

Parameters	(In Rs. Millions)		
	1st FY (March 31, 2025)*	2nd FY (March 31, 2026)*	3rd FY (March 31, 2027)*
Income from Operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available
<i>*Financials not disclosed as reporting for the relevant fiscal year has not been completed.</i>			

#### 7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited  
The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)*	Not Available
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available
<i>*Trading status not disclosed as the relevant fiscal year has not been completed.</i>	

#### 8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)*		Not Available
(ii) at the end of 2nd FY (March 31, 2026)*		Not Available
(iii) at the end of 3rd FY (March 31, 2027)*		Not Available
<i>* Changes in Directors not disclosed as the relevant fiscal year has not been completed.</i>		

#### 9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

<b>10 Status of utilization of issue proceeds</b>	
(i) as disclosed in the offer document	Not Applicable
(ii) Actual utilization	Not Applicable
(iii) Reasons for deviation, if any	Not Applicable

**11 Comments of monitoring agency**

(a) Comments on use of funds	Not Applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

**12 Pricing Data**

Issue Price (Rs.):	441.00
Designated Stock Exchange:	BSE
Listing Date:	06-Dec-24

Price parameters	At close of listing day (December 6, 2024)	At close of 30th calendar day from listing day <sup>(1)</sup>	At close of 90th calendar day from listing day <sup>(2) (3)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2025) <sup>(2) (3)</sup>		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange <sup>(4)</sup>	417.95	377.85	Not Applicable	Not Applicable	Not Applicable	Not Applicable
BSE Sensex <sup>(4)</sup>	81,510.05	79,223.11	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Sectoral Index <sup>(5)</sup>	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2026) <sup>(2) (3)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2027) <sup>(2) (3)</sup>		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange <sup>(4)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
BSE Sensex <sup>(4)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index <sup>(5)</sup>	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable

Source: BSE website

Note:

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
- (2) High and Low based on intra day prices
- (3) Pricing data not disclosed as the relevant period/ fiscal year has not completed
- (4) In case of any reporting day falling on a holiday, next trading day prices/values have been disclosed.
- (5) The Company is not part of any Sectoral index

## 13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2025) <sup>(2)</sup>	At the end of 2nd FY (March 31, 2026) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2027) <sup>(2)</sup>
EPS	<b>Issuer:</b>			
	Consolidated (Basic)	4.43	Not Available	Not Available
	<b>Peer Group:</b>			
	Dr Lal PathLabs	43.05	Not Available	Not Available
	Metropolis Healthcare	24.95	Not Available	Not Available
	Thyrocare	13.42	Not Available	Not Available
	Vijaya Diagnostic	11.62	Not Available	Not Available
<b>Industry Avg:</b>	<b>23.26</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>
Price to Earnings Ratio (P/E)	<b>Issuer:</b>			
	Consolidated (Basic)	NA	Not Available	Not Available
	<b>Peer Group:</b>			
	Dr Lal PathLabs	77.08	Not Available	Not Available
	Metropolis Healthcare	89.61	Not Available	Not Available
	Thyrocare	65.52	Not Available	Not Available
	Vijaya Diagnostic	86.40	Not Available	Not Available
<b>Industry Avg:</b>	<b>79.65</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>
RoNW(%)	<b>Issuer:</b>			
	Consolidated (Basic)	14.09%	Not Available	Not Available
	<b>Peer Group:</b>			
	Dr Lal PathLabs	20.35%	Not Available	Not Available
	Metropolis Healthcare	12.26%	Not Available	Not Available
	Thyrocare	13.34%	Not Available	Not Available
	Vijaya Diagnostic	19.77%	Not Available	Not Available
<b>Industry Avg:</b>	<b>16.43%</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>
NAV per Equity Share	<b>Issuer:</b>			
	Consolidated (Basic)	33.66	Not Available	Not Available
	<b>Peer Group:</b>			
	Dr Lal PathLabs	221.53	Not Available	Not Available
	Metropolis Healthcare	213.98	Not Available	Not Available
	Thyrocare	99.48	Not Available	Not Available
	Vijaya Diagnostic	64.21	Not Available	Not Available
<b>Industry Avg:</b>	<b>149.80</b>	<b>N.A.</b>	<b>N.A.</b>	<b>N.A.</b>

**Notes:**

(1) Sourced from Prospectus dated December 3, 2024.

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) Basic Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares outstanding during the fiscal year.

Earnings per share calculations are in accordance with the notified Ind AS 33 'Earnings per share' notified accounting standard by the Companies (Indian Accounting Standards) Rules of 2015 (as amended).

(ii) Diluted Earnings per Share (Rs.) = net profit after tax and adjustments, attributable for equity shareholders (after adjusting profit impact of dilutive potential equity shares, if any) / the aggregate of weighted average number of Equity shares outstanding during the year and the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

(iii) Total Income = Revenue from Operations and Other Income

(iv) P/E (Basic/Diluted) - Closing Market Price at the end of relevant fiscal year end on NSE/ Basic/Diluted EPS

(v) Return on Net Worth (%) = Net profit after tax, available for equity shareholders / Net worth at the end of the fiscal year.

(vi) Net Asset Value per Equity Share = Net worth at the end of the fiscal year./ Number of equity shares outstanding as at the end of fiscal year

## 14 Any other material information

Date of disclosure	Announcement
Nil	Nil

Source: BSE / NSE website

**Note:** The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.